Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Rating of “Buy” from Analysts

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received an average recommendation of “Buy” from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $17.00.

Several equities research analysts recently commented on IVA shares. UBS Group began coverage on Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target for the company. Leerink Partners initiated coverage on Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 price objective on the stock. Barclays assumed coverage on Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 target price for the company. Guggenheim reduced their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a research report on Wednesday, January 28th.

Hedge Funds Weigh In On Inventiva

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning acquired a new stake in shares of Inventiva during the 2nd quarter worth approximately $32,000. Virtu Financial LLC acquired a new position in Inventiva in the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new position in Inventiva in the fourth quarter worth approximately $84,000. NewEdge Advisors LLC acquired a new stake in Inventiva during the third quarter worth $116,000. Finally, Cerity Partners LLC acquired a new stake in Inventiva during the fourth quarter worth $93,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Price Performance

IVA opened at $5.99 on Friday. The company’s 50 day simple moving average is $6.18 and its two-hundred day simple moving average is $5.36. Inventiva has a 1-year low of $2.70 and a 1-year high of $7.98.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.